Product Pipeline

PTG-100: A GI-restricted α4β7 integrin-specific antagonist for the treatment of moderate-to-severe UC

PTG-200: A potential first-in-class oral IL-23R antagonist for the treatment of moderate-to-severe IBD

PTG-300: An Injectable hepcidin mimetic being developed to treat iron overload disorders

Latest News

July 8, 2016

William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board read more

May 17, 2016

Protagonist Therapeutics to Present New Data for PTG-100 and PTG-200 at Digestive Disease Week 2016 read more

February 17, 2016

Protagonist Therapeutics Names Thomas P. O’Neil Chief Financial Officer read more

Upcoming Events

August 21-25, 2016

252nd American Chemical Society National Meeting & Exposition
Philadelphia, PA